vs

Side-by-side financial comparison of CENTERSPACE (CSR) and Krystal Biotech, Inc. (KRYS). Click either name above to swap in a different company.

Krystal Biotech, Inc. is the larger business by last-quarter revenue ($107.1M vs $65.1M, roughly 1.6× CENTERSPACE). Krystal Biotech, Inc. runs the higher net margin — 48.0% vs -23.0%, a 71.0% gap on every dollar of revenue. On growth, Krystal Biotech, Inc. posted the faster year-over-year revenue change (17.5% vs -3.0%). Over the past eight quarters, Krystal Biotech, Inc.'s revenue compounded faster (53.8% CAGR vs 0.0%).

Centerspace is a real estate investment company specializing in the ownership, operation, and development of high-quality multifamily residential properties. Its core operating markets cover the U.S. Midwest and Mountain West regions, serving diverse renter segments with both affordable and premium housing options, while focusing on tenant experience and long-term asset value growth.

Krystal Biotech, Inc. is a clinical-stage biotechnology company specializing in the research, development and commercialization of novel gene therapies for rare, serious dermatological diseases with high unmet medical needs. It primarily serves patients across North America and Europe, focusing on monogenic skin disorders that lack effective standard treatment options.

CSR vs KRYS — Head-to-Head

Bigger by revenue
KRYS
KRYS
1.6× larger
KRYS
$107.1M
$65.1M
CSR
Growing faster (revenue YoY)
KRYS
KRYS
+20.5% gap
KRYS
17.5%
-3.0%
CSR
Higher net margin
KRYS
KRYS
71.0% more per $
KRYS
48.0%
-23.0%
CSR
Faster 2-yr revenue CAGR
KRYS
KRYS
Annualised
KRYS
53.8%
0.0%
CSR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CSR
CSR
KRYS
KRYS
Revenue
$65.1M
$107.1M
Net Profit
$-15.0M
$51.4M
Gross Margin
Operating Margin
41.5%
Net Margin
-23.0%
48.0%
Revenue YoY
-3.0%
17.5%
Net Profit YoY
-258.1%
13.0%
EPS (diluted)
$-0.49
$1.69

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSR
CSR
KRYS
KRYS
Q1 26
$65.1M
Q4 25
$66.6M
$107.1M
Q3 25
$71.4M
$97.8M
Q2 25
$68.5M
$96.0M
Q1 25
$67.1M
$88.2M
Q4 24
$66.4M
$91.1M
Q3 24
$65.0M
$83.8M
Q2 24
$65.0M
$70.3M
Net Profit
CSR
CSR
KRYS
KRYS
Q1 26
$-15.0M
Q4 25
$-18.4M
$51.4M
Q3 25
$53.8M
$79.4M
Q2 25
$-14.5M
$38.3M
Q1 25
$-3.7M
$35.7M
Q4 24
$-5.1M
$45.5M
Q3 24
$-1.0M
$27.2M
Q2 24
$-1.3M
$15.6M
Gross Margin
CSR
CSR
KRYS
KRYS
Q1 26
Q4 25
96.5%
Q3 25
96.5%
Q2 25
96.5%
Q1 25
96.4%
Q4 24
96.5%
Q3 24
96.6%
Q2 24
96.6%
Operating Margin
CSR
CSR
KRYS
KRYS
Q1 26
Q4 25
-15.9%
41.5%
Q3 25
42.3%
Q2 25
-9.9%
40.9%
Q1 25
7.1%
41.0%
Q4 24
4.3%
45.4%
Q3 24
9.8%
26.8%
Q2 24
11.1%
12.2%
Net Margin
CSR
CSR
KRYS
KRYS
Q1 26
-23.0%
Q4 25
-27.7%
48.0%
Q3 25
75.3%
81.2%
Q2 25
-21.2%
39.9%
Q1 25
-5.6%
40.5%
Q4 24
-7.6%
49.9%
Q3 24
-1.6%
32.4%
Q2 24
-2.0%
22.2%
EPS (diluted)
CSR
CSR
KRYS
KRYS
Q1 26
$-0.49
Q4 25
$-1.08
$1.69
Q3 25
$3.19
$2.66
Q2 25
$-0.87
$1.29
Q1 25
$-0.22
$1.20
Q4 24
$-0.31
$1.53
Q3 24
$-0.40
$0.91
Q2 24
$-0.19
$0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSR
CSR
KRYS
KRYS
Cash + ST InvestmentsLiquidity on hand
$7.6M
$496.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$695.0M
$1.2B
Total Assets
$1.9B
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSR
CSR
KRYS
KRYS
Q1 26
$7.6M
Q4 25
$12.8M
$496.3M
Q3 25
$12.9M
$392.6M
Q2 25
$12.4M
$353.8M
Q1 25
$11.9M
$308.8M
Q4 24
$12.0M
$344.9M
Q3 24
$14.5M
$374.0M
Q2 24
$14.3M
$345.8M
Total Debt
CSR
CSR
KRYS
KRYS
Q1 26
Q4 25
$1.0B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$955.5M
Q4 24
$955.4M
Q3 24
$921.3M
Q2 24
$931.7M
Stockholders' Equity
CSR
CSR
KRYS
KRYS
Q1 26
$695.0M
Q4 25
$719.2M
$1.2B
Q3 25
$748.6M
$1.1B
Q2 25
$710.1M
$1.0B
Q1 25
$636.8M
$984.7M
Q4 24
$752.0M
$946.4M
Q3 24
$672.5M
$885.8M
Q2 24
$680.7M
$838.9M
Total Assets
CSR
CSR
KRYS
KRYS
Q1 26
$1.9B
Q4 25
$1.9B
$1.3B
Q3 25
$2.1B
$1.2B
Q2 25
$2.0B
$1.1B
Q1 25
$1.9B
$1.1B
Q4 24
$1.9B
$1.1B
Q3 24
$1.9B
$982.3M
Q2 24
$1.9B
$917.7M
Debt / Equity
CSR
CSR
KRYS
KRYS
Q1 26
Q4 25
1.42×
Q3 25
1.53×
Q2 25
1.57×
Q1 25
1.50×
Q4 24
1.27×
Q3 24
1.37×
Q2 24
1.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSR
CSR
KRYS
KRYS
Operating Cash FlowLast quarter
$77.5M
Free Cash FlowOCF − Capex
$75.4M
FCF MarginFCF / Revenue
70.4%
Capex IntensityCapex / Revenue
0.3%
2.0%
Cash ConversionOCF / Net Profit
1.51×
TTM Free Cash FlowTrailing 4 quarters
$188.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSR
CSR
KRYS
KRYS
Q1 26
Q4 25
$98.5M
$77.5M
Q3 25
$35.1M
$39.7M
Q2 25
$25.3M
$52.7M
Q1 25
$25.4M
$31.0M
Q4 24
$98.2M
$52.8M
Q3 24
$32.3M
$58.9M
Q2 24
$22.9M
$-4.2M
Free Cash Flow
CSR
CSR
KRYS
KRYS
Q1 26
Q4 25
$64.3M
$75.4M
Q3 25
$25.7M
$38.0M
Q2 25
$15.5M
$50.8M
Q1 25
$20.4M
$24.8M
Q4 24
$41.6M
$52.0M
Q3 24
$20.5M
$57.8M
Q2 24
$9.1M
$-5.3M
FCF Margin
CSR
CSR
KRYS
KRYS
Q1 26
Q4 25
96.5%
70.4%
Q3 25
36.0%
38.8%
Q2 25
22.7%
52.9%
Q1 25
30.4%
28.1%
Q4 24
62.6%
57.1%
Q3 24
31.5%
69.0%
Q2 24
14.0%
-7.5%
Capex Intensity
CSR
CSR
KRYS
KRYS
Q1 26
0.3%
Q4 25
51.3%
2.0%
Q3 25
13.1%
1.7%
Q2 25
14.2%
2.0%
Q1 25
7.5%
7.0%
Q4 24
85.3%
0.9%
Q3 24
18.2%
1.2%
Q2 24
21.2%
1.6%
Cash Conversion
CSR
CSR
KRYS
KRYS
Q1 26
Q4 25
1.51×
Q3 25
0.65×
0.50×
Q2 25
1.38×
Q1 25
0.87×
Q4 24
1.16×
Q3 24
2.17×
Q2 24
-0.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons